Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology company focused on developing genetic medicines and other advanced therapeutics to treat neurological diseases. The company's mission centers on leveraging human genetics to modify the course of and ultimately cure neurological conditions affecting the… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Voyager Therapeutics, Inc. does
In the company’s own words
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology company focused on developing genetic medicines and other advanced therapeutics to treat neurological diseases. The company's mission centers on leveraging human genetics to modify the course of and ultimately cure neurological conditions affecting the central nervous system.
The company operates through a portfolio of wholly-owned programs and collaborative partnerships. Its proprietary pipeline prioritizes Alzheimer's disease treatment, featuring two tau-targeting programs: VY1706, a tau silencing gene therapy delivered intravenously using a TRACER capsid containing vectorized small interfering RNA, and VY7523, an anti-tau monoclonal antibody currently in Phase 1 clinical trials. Voyager is also developing a non-viral therapeutic leveraging its proprietary Voyager NeuroShuttle platform for undisclosed neurological diseases.
The company's core technology platform, TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), enables discovery of adeno-associated virus capsids with robust blood-brain-barrier penetration and enhanced central nervous system tropism. This platform has generated novel capsids and identified associated receptors to facilitate high brain penetration through intravenous dosing. The Voyager NeuroShuttle platform represents a non-viral delivery system leveraging receptor-binding molecules to transport neurotherapeutics across the blood-brain barrier.
Beyond wholly-owned programs, Voyager maintains collaborative relationships with major pharmaceutical partners including Neurocrine Biosciences, Novartis Pharma AG, and Alexion, AstraZeneca Rare Disease. These partnerships address conditions including Friedreich's ataxia, Gaucher disease, Parkinson's disease, spinal muscular atrophy, and Huntington's disease. Collaborations have delivered over $500 million in non-dilutive funding to date, with potential future milestone payments reaching $6.8 billion across the partnered portfolio.
The company also maintains an option agreement with Transition Bio to develop selective small molecules targeting TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia treatment. Voyager's website is located at www.voyagertherapeutics.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1640266
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Voyager Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Voyager Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Voyager Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Voyager Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Voyager Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”